OMass: validating mass spec for targeting the nearly undruggable

OMass is using its mass spectrometry platform to discover small molecules against difficult-to-drug targets and has now raised nearly $100 million to push its first-in-class pipeline into the clinic.

On Thursday, Oxford-based OMass Therapeutics Ltd. raised £75.5 million ($96.3 million) in a series B round led by new investors GV, Northpond Ventures and Sanofi Ventures...